Schizophrenia News and Research

Latest Schizophrenia News and Research

Personalized approaches to treating intellectual disability

Scientists from the Florida campus of The Scripps Research Institute have produced an approach that protects animal models against a type of genetic disruption that causes intellectual disability, including serious memory impairments and altered anxiety levels.

22 Jan 2015

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%.

20 Jan 2015

Researchers identify novel life-preserving circuit responsible for recognizing threats

Our existence depends on a bit of evolutionary genius aptly nicknamed "fight or flight." But where in our brain does the alarm first go off, and what other parts of the brain are mobilized to express fear and remember to avoid danger in the future?

20 Jan 2015

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia.

20 Jan 2015

Venom of cone snails provides leads for possible treatment of cancer, addiction

While considered a delicacy in some parts of the world, snails have found a more intriguing use to scientists and the medical profession offering a plethora of research possibilities. Cone snails are marine mollusks, just as conch, octopi and squid, but they capture their prey using venom.

15 Jan 2015

State and federal prisoners not receiving adequate mental health care

A significant portion of state and federal prisoners are not receiving treatment for mental health conditions, according to research by The University of Texas Health Science Center at Houston School of Public Health.

12 Jan 2015

Longitudinal course of schizophrenia negative symptoms revealed

Schizophrenia negative symptoms are relatively stable in the first year for most patients after they begin antipsychotic medication but research suggests around a quarter will experience exacerbation or relapse.

7 Jan 2015

Comorbid OCD not uncommon in bipolar disorder

Co-occurrence of obsessive compulsive disorder in patients with bipolar disorder type I is not uncommon and is associated with increased functional disability, research findings indicate.

7 Jan 2015

CET ‘feasible’ in schizophrenia patients with substance misuse

Patients with schizophrenia and comorbid substance abuse diagnoses are able to benefit from cognitive enhancement therapy, preliminary research suggests.

7 Jan 2015

McGill University researchers identify network of complex neurons in the brain

Our ability to pay attention to certain things while ignoring distractions determines how good we are at a given task, whether it is driving a car or doing brain surgery. A research team at McGill University has for the first time convincingly identified a network of neurons in a particular area of the brain, the lateral prefrontal cortex, that interact with one another to promptly filter visual information while at the same time ignoring distractions. It's a discovery with potentially far reaching implications for people who suffer from diseases such as autism, ADHD and schizophrenia.

7 Jan 2015

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors.

6 Jan 2015

LIBD announces significant advances in identifying causes of schizophrenia, brain disorders

The Lieber Institute for Brain Development (LIBD) announces significant advances in identifying the causes of schizophrenia and related developmental brain disorders and translating these findings into new treatment strategies.

31 Dec 2014

Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, and its commercial and development partner Zambon S.p.A., an international pharmaceutical company, announced today that the NDA for safinamide has been re-submitted to the US FDA.

29 Dec 2014

Intriguing small molecule directs activity of key ‘clock proteins’

In research published in Nature Communications, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports intriguing findings about a small molecule that directs the activity of key "clock proteins," offering the potential to manage circadian rhythm and treat problems that are associated with its dysfunction, like sleep and anxiety disorders.

24 Dec 2014

Social environment not linked to UHR psychosis transition

Research indicates that social deprivation and migrant status do not influence the risk of transition to psychosis in ultra-high-risk individuals.

18 Dec 2014

Health promotion program reduces cardiovascular risk in obese people with serious mental illness

A health promotion program, called In SHAPE, specifically designed for people with serious mental illness, produced more fit participants and significant weight loss than a control group where participants only received a gym membership.

18 Dec 2014

New study finds high suicide rates among transgender veterans

Veterans of the U.S. armed forces who have received a diagnosis consistent with transgender status are more likely to have serious suicidal thoughts and plans and to attempt suicide.

18 Dec 2014

Antipsychotic polypharmacy prevalent despite efficacy doubts

Results of a retrospective study suggest that around a quarter of patients with schizophrenia receive antipsychotic polypharmacy, despite a lack of evidence for the approach.

17 Dec 2014

Novel technique to identify biological markers in brain development

With a unique, multi-faceted approach, researchers at the Lieber Institute for Brain Development have quantified the effect of previously unidentified anomalies in genetic expression that determine how the human brain develops from its earliest stages.

17 Dec 2014

Cerebellar cortical volume reduction specific to schizophrenia

Reduced cerebellar cortical volume occurs only in patients with schizophrenia, rather than all those with psychosis, say researchers.

10 Dec 2014

Schizophrenia News and Research

Latest Schizophrenia News and Research

Personalized approaches to treating intellectual disability

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Researchers identify novel life-preserving circuit responsible for recognizing threats

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Venom of cone snails provides leads for possible treatment of cancer, addiction

State and federal prisoners not receiving adequate mental health care

Longitudinal course of schizophrenia negative symptoms revealed

Comorbid OCD not uncommon in bipolar disorder

CET ‘feasible’ in schizophrenia patients with substance misuse

McGill University researchers identify network of complex neurons in the brain

FDA receives Actavis' NDA resubmission for cariprazine

LIBD announces significant advances in identifying causes of schizophrenia, brain disorders

Newron, Zambon announce re-submission of safinamide NDA to FDA

Intriguing small molecule directs activity of key ‘clock proteins’

Social environment not linked to UHR psychosis transition

Health promotion program reduces cardiovascular risk in obese people with serious mental illness

New study finds high suicide rates among transgender veterans

Antipsychotic polypharmacy prevalent despite efficacy doubts

Novel technique to identify biological markers in brain development

Cerebellar cortical volume reduction specific to schizophrenia

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Schizophrenia News and Research

Latest Schizophrenia News and Research

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in